Yitian Zhou

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF GENETICS AND GENOMICS. 2024;51(11):1228-1236
Population-scale variability of the human UDP-glycosyltransferase gene family
Gonzalez-Padilla D; Camara MD; Lauschke VM; Zhou Y
Article: PHARMACOGENOMICS JOURNAL. 2024;24(3):17
APF2: an improved ensemble method for pharmacogenomic variant effect prediction
Zhou Y; Pirmann S; Lauschke VM
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2024;68(5):e01390-e01323
Population-specific variations in KCNH2 predispose patients to delayed ventricular repolarization upon dihydroartemisinin-piperaquine therapy
Camara MD; Zhou Y; Dara A; Tekete MM; de Sousa TN; Sissoko S; Dembele L; Ouologuem N; Togo AH; Alhousseini ML; Fofana B; Sagara I; Djimde AA; Gil PJ; Lauschke VM
Article: HUMAN GENOMICS. 2024;18(1):40
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences
Camara MD; Zhou Y; De Sousa TN; Gil JP; Djimde AA; Lauschke VM
Article: NPJ GENOMIC MEDICINE. 2023;8(1):24
Structural variation of the coding and non-coding human pharmacogenome
Tremmel R; Zhou Y; Schwab M; Lauschke VM
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2023;113(3):712-723
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations
Khor CC; Winter S; Sutiman N; Muerdter TE; Chen S; Lim JSL; Li Z; Li J; Sim KS; Ganchev B; Eccles D; Eccles B; Tapper W; Zgheib NKK; Tfayli A; Ng RCH; Yap YS; Lim E; Wong M; Wong NS; Ang PCS; Dent R; Tremmel R; Klein K; Schaeffeler E; Zhou Y; Lauschke VMM; Eichelbaum M; Schwab M; Brauch HBB; Chowbay B; Schroth W
Article: HUMAN GENOMICS. 2023;17(1):15
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences
Zhou Y; Nevosadova L; Eliasson E; Lauschke VMM
Article: THE LANCET. 2023;401(10374):347-356
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
Swen JJ; van der Wouden CH; Manson LEN; Abdullah-Koolmees H; Blagec K; Blagus T; Boehringer S; Cambon-Thomsen A; Cecchin E; Cheung K-C; Deneer VHM; Dupui M; Ingelman-Sundberg M; Jonsson S; Joefield-Roka C; Just KS; Karlsson MO; Konta L; Koopmann R; Kriek M; Lehr T; Mitropoulou C; Rial-Sebbag E; Rollinson V; Roncato R; Samwald M; Schaeffeler E; Skokou M; Schwab M; Steinberger D; Stingl JC; Tremmel R; Turner RM; van Rhenen MH; Fajardo CLD; Dolzan V; Patrinos GP; Pirmohamed M; Sunder-Plassmann G; Toffoli G; Guchelaar H-J
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2023;280:237-260
Challenges Related to the Use of Next-Generation Sequencing for the Optimization of Drug Therapy.
Zhou Y; Lauschke VM
Article: ISCIENCE. 2022;25(12):105506
Scellseg: A style-aware deep learning tool for adaptive cell instance segmentation by contrastive fine-tuning
Xun D; Chen D; Zhou Y; Lauschke VM; Wang R; Wang Y
Article: PHARMACOGENOMICS JOURNAL. 2022;22(5-6):284-293
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data
Zhou Y; Lauschke VM
Article: BIOMEDICINE & PHARMACOTHERAPY. 2022;154:113644
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
De Mattia E; Silvestri M; Polesel J; Ecca F; Mezzalira S; Scarabel L; Zhou Y; Roncato R; Lauschke VM; Calza S; Spina M; Puglisi F; Toffoli G; Cecchin E
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2022;109(6):1077-1091
Genome-wide association meta-analysis identifies 48 risk variants and highlights the role of the stria vascularis in hearing loss
Trpchevska N; Freidin MB; Broer L; Oosterloo BC; Yao S; Zhou Y; Vona B; Bishop C; Bizaki-Vallaskangas A; Canlon B; Castellana F; Chasman DI; Cherny S; Christensen K; Concas MP; Correa A; Elkon R; Mengel-From J; Gao Y; Giersch ABS; Girotto G; Gudjonsson A; Gudnason V; Heard-Costa NL; Hertzano R; v.B. Hjelmborg J; Hjerling-Leffler J; Hoffman HJ; Kaprio J; Kettunen J; Krebs K; Kahler AK; Lallemend F; Launer LJ; Lee I-M; Leonard H; Li C-M; Lowenheim H; Magnusson PKE; van Meurs J; Milani L; Morton CC; Makitie A; Nalls MA; Nardone GG; Nygaard M; Palviainen T; Pratt S; Quaranta N; Ramo J; Saarentaus E; Sardone R; Satizabal CL; Schweinfurth JM; Seshadri S; Shiroma E; Shulman E; Simonsick E; Spankovich C; Tropitzsch A; Lauschke VM; Sullivan PF; Goedegebure A; Cederroth CR; Williams FMK; Nagtegaal AP
Article: PHARMACEUTICS. 2022;14(5):944
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia
Dagli-Hernandez C; Borges JB; Rodrigues Marcal EDS; Costa de Freitas RC; Mori AA; Goncalves RM; Faludi AA; de Oliveira VF; Ferreira GM; Bastos GM; Zhou Y; Lauschke VM; Cerda A; Hirata MH; Crespo Hirata RD
Article: PHARMACOLOGICAL RESEARCH. 2022;176:106087
Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics
Siamoglou S; Koromina M; Hishinuma E; Yamazaki S; Tsermpini E-E; Kordou Z; Fukunaga K; Chantratita W; Zhou Y; Lauschke VM; Mushiroda T; Hiratsuka M; Patrinos GP
Article: GENETICS IN MEDICINE. 2022;24(1):157-169
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
Yang M; Johnsson P; Brautigam L; Yang XR; Thrane K; Gao J; Tobin NP; Zhou Y; Yu R; Nagy N; Engstrom PG; Tuominen R; Eriksson H; Lundeberg J; Tucker MA; Goldstein AM; Egyhazi-Brage S; Zhao J; Cao Y; Hoiom V
Article: SCIENCE ADVANCES. 2021;7(36):eabi6856
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine
Zhou Y; Arribas GH; Turku A; Juergenson T; Mkrtchian S; Krebs K; Wang Y; Svobodova B; Milani L; Schulte G; Korabecny J; Gastaldello S; Lauschke VM
Journal article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(8):1095-1111
Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes
Wang T; Zhou Y; Cao G
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2021;65(7):e0027521-10.1128/aac.00221
Pharmacogene Sequencing of a Gabonese Population with Severe Plasmodium falciparum Malaria Reveals Multiple Novel Variants with Putative Relevance for Antimalarial Treatment
Pernaute-Lau L; Adegnika AA; Zhou Y; Zinsou JF; Gil JP; Krishna S; Kremsner PG; Lauschke VM; Velavan TP
Journal article: PHARMACOGENOMICS RESEARCH AND PERSONALIZED MEDICINE. 2021;0(0):0
Should we test for SLCO1B1 genotype before prescribing statins? A discussion of clinical trial results
Zhou Y; Lauschke VM
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2021;109(1):160-174
Global Frequencies of Clinically ImportantHLAAlleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing
Zhou Y; Krebs K; Milani L; Lauschke VM
Article: BRITISH JOURNAL OF CANCER. 2020;123(12):1782-1789
Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier
Zhou Y; Dagli Hernandez C; Lauschke VM
Article: HUMAN GENETICS. 2020;139(5):623-646
Ethnogeographic and inter-individual variability of human ABC transporters
Xiao Q; Zhou Y; Lauschke VM
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;146(9):2475-2487
Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients
Xiao Q; Zhou Y; Winter S; Buettner F; Schaeffeler E; Schwab M; Lauschke VM
Article: MOLECULAR PHARMACEUTICS. 2020;17(4):1170-1181
In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na⁺-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1)
Russell LE; Zhou Y; Lauschke VM; Kim RB
Article: COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2020;18:52-58
Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition
Zhou Y; Lauschke VM
Article: PHARMACOGENOMICS. 2019;20(15):1085-1092
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma
Lauschke VM; Nordling A; Zhou Y; Fontalva S; Barragan I; Ingelman-Sundberg M
Article: PHARMACOGENOMICS JOURNAL. 2019;19(2):115-126
An optimized prediction framework to assess the functional impact of pharmacogenetic variants
Zhou Y; Mkrtchian S; Kumondai M; Hiratsuka M; Lauschke VM
Article: JOURNAL OF LIPID RESEARCH. 2018;59(10):1987-2000
Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk
Zhou Y; Magi R; Milani L; Lauschke VM
Article: JOURNAL OF MEDICAL GENETICS. 2018;55(9):617-627
Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews
Zhou Y; Lauschke VM
Article: TOXICOLOGICAL SCIENCES. 2018;163(2):655-665
Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions
Vorrink SU; Zhou Y; Ingelman-Sundberg M; Lauschke VM
Article: HUMAN GENOMICS. 2018;12(1):26
Integrating rare genetic variants into pharmacogenetic drug response predictions
Ingelman-Sundberg M; Mkrtchian S; Zhou Y; Lauschke VM
Journal article: PROCEEDINGS FOR ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY. 2018;WCP2018(0):po4-9-16
Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures
Vorrink SU; Zhou Y; Ingelman-Sundberg M; Lauschke VM
Article: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2017;102(4):688-700
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects
Zhou Y; Ingelman-Sundberg M; Lauschke VM
Article: SCIENTIFIC REPORTS. 2014;4:6978
Trend of telomerase activity change during human iPSC self-renewal and differentiation revealed by a quartz crystal microbalance based assay
Zhou Y; Zhou P; Xin Y; Wang J; Zhu Z; Hu J; Wei S; Ma H
Article: ACS APPLIED MATERIALS & INTERFACES. 2014;6(11):8313-8319
Molecular Composition, Grafting Density and Film Area Affect the Swelling-Induced Au-S Bond Breakage
Lv B; Zhou Y; Cha W; Wu Y; Hu J; Li L; Chi L; Ma H
Visa fler

Alla övriga publikationer

Review: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2024;17(3):213-223
Next-generation sequencing in pharmacogenomics - fit for clinical decision support?
Zhou Y; Lauschke VM
Review: ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. 2024;64:33-51
Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward
Lauschke VM; Zhou Y; Ingelman-Sundberg M
Review: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2023
Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance
Tremmel R; Pirmann S; Zhou Y; Lauschke VM
Conference publication: NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. 2023;396:S52
PharmFreq: a comprehensive database of worldwide allelic frequencies in clinically important pharmacogenes
Tremmel R; Zhou Y; Nevosadova L; Laarif S; Eliasson E; Lauschke VM
Conference publication: NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. 2023;396:S52
Multi-dimensional omics profiling of a biobank reveals the interindividual variability of ADME gene expression in human liver
Klein K; Nies AT; Haag M; Hofmann U; Artursson P; Handin N; Burk O; Tremmel R; Winter S; Zhou Y; Schaeffeler E; Zanger UM; Lauschke VM; Schwab M
Editorial comment: ANNALS OF TRANSLATIONAL MEDICINE. 2022;10(23):1293-0
Should we test for SLCO1B1 genotype before prescribing statins? A discussion of clinical trial results
Zhou Y; Lauschke VM
Review: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2022;131(6):452-464
A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing
Zhou Y; Koutsilieri S; Eliasson E; Lauschke VM
Review: TRENDS IN PHARMACOLOGICAL SCIENCES. 2022;43(10):852-865
Challenges and opportunities associated with rare-variant pharmacogenomics br
Zhou Y; Tremmel R; Schaeffeler E; Schwab M; Lauschke VM
Conference publication: 2022;:30-35
Profile genetic variability and population diversity of C-C chemokine receptor type 5 (CCR5) gene in HIV infection
Sun Y; Zhou Y
Review: HUMAN GENETICS. 2022;141(6):1113-1136
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
Zhou Y; Lauschke VM
Review: PHARMACOLOGICAL REPORTS. 2022;74(1):47-66
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts
Dagli-Hernandez C; Zhou Y; Lauschke VM; Genvigir FDV; Hirata TDC; Hirata MH; Hirata RDC
Review: PHARMACOLOGICAL REVIEWS. 2022;74(1):141-206
Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives
Youhanna S; Kemas AM; Preiss L; Zhou Y; Shen JX; Cakal SD; Paqualini FS; Goparaju SK; Shafagh RZ; Lind JU; Sellgren CM; Lauschke VM
Review: ENDOCRINE, METABOLIC AND IMMUNE DISORDERS - DRUG TARGETS. 2022;22(13):1263-1275
Pharmacogenomics of Antihypertensive Drugs in Brazil: Recent Progress and Clinical Implications
Genvigir FDV; Dagli-Hernandez C; Hirata TDC; Zhou Y; Lauschke VM; Hirata MH; Hirata RDC
Book chapter: COMPREHENSIVE PHARMACOLOGY. 2022;p. 53-83
2.05 Computational Methods and Approaches in Pharmacogenomic Research
Zhou Y; Lauschke VM
Preprint: BIORXIV. 2021
Scellseg: a style-aware cell instance segmentation tool with pre-training and contrastive fine-tuning
Xun D; Chen D; Zhou Y; Lauschke V; Wang R; Wang Y
Review: MOLECULAR DIAGNOSIS AND THERAPY. 2021;25(6):735-755
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients
Crespo Hirata TD; Dagli-Hernandez C; Dalla Vecchia Genvigir F; Lauschke VM; Zhou Y; Hirata MH; Crespo Hirata RD
Thesis / dissertation: 2021
Assessing the importance of rare genetic variants for drug response
Zhou, Yitian
Review: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2021;110(3):626-636
Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability
Zhou Y; Lauschke VM
Review: DRUG METABOLISM REVIEWS. 2021;53(2):253-278
Pharmacogenomics in the era of next generation sequencing - from byte to bedside
Russell LE; Zhou Y; Almousa AA; Sodhi JK; Nwabufo CK; Lauschke VM
Editorial comment: FRONTIERS IN GENETICS. 2021;12:736626
Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
Hiratsuka M; Zhou Y; Lauschke VM
Review: PHARMACOGENOMICS. 2020;21(18):1299-1310
The impact of variants in ATP-binding cassette transporters on breast cancer treatment
Xiao Q; Zhou Y; Lauschke VM
Review: PHARMACOLOGY AND THERAPEUTICS. 2019;197:122-152
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Lauschke VM; Zhou Y; Ingelman-Sundberg M
Review: FRONTIERS IN PHARMACOLOGY. 2019;10:1093
Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury
Zhou Y; Shen JX; Lauschke VM
Review: FRONTIERS IN PHARMACOLOGY. 2018;9:1437
Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data
Zhou Y; Fujikura K; Mkrtchian S; Lauschke VM
Conference publication: BASIC AND CLINICAL PHARMACOLOGY AND TOXICOLOGY. 2018;123:5
AN OPTIMIZED PREDICTION FRAMEWORK TO ASSESS THE FUNCTIONAL IMPACT OF PHARMACOGENETIC VARIANTS
Zhou Y; Mkrtchian S; Kumondai M; Hiratsuka M; Lauschke V
Visa fler

Forskningsbidrag

Precision Medicine by personalized dosing of capecitabine and tamoxifen in breast cancer – advanced pharmacogene sequencing, phenotype markers and modeling of patient-unique genetic variants
Cancerfonden

Anställningar

Postdoktor, Fysiologi och farmakologi, Karolinska Institutet, 2023-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för fysiologi och farmakologi, Karolinska Institutet, 2021
Medicine Masterexamen, Karolinska Institutet, 2017

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI